$548.05
7.791.44%
가까이에: Aug 21, 5:00 PM EST
$548.05
N/A
시간외: 4:35 PM EST
Benzinga
Benzinga
Benzinga
금요일, 8월 21
Vertex Pharmaceuticals Inc
VRTXNASDAQ
Vertex Pharmaceuticals Earnings & Forecasts
Vertex Pharmaceuticals (VRTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Vertex Pharmaceuticals Guidance
Vertex Pharmaceuticals (VRTX)는 8월 3, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $13.1B - $13.2B 범위로 예상했습니다.
이전 가이던스와 비교하여 Vertex Pharmaceuticals는 매출 전망치를 이전 범위인 유지됨에서 $12.95B - $13.1B로 상향 조정했습니다.
Vertex Pharmaceuticals은 16과 10월 27, 2022 사이에 8월 3, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $4.63 | $4.18 | $4.85 | $4.35 |
| Actual | $4.73 | $4.47 | $5.03 | $4.80 |
| Surprise | +2.16% | +6.94% | +3.71% | +10.3% |
| Revenue | ||||
| Estimate | $3.21B | $2.99B | $3.17B | $3.05B |
| Actual | $3.33B | $2.99B | $3.19B | $3.08B |
| Surprise | +3.74% | -0.24% | +0.54% | +0.80% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $4.80 | $4.78 | $4.64 | $4.88 |
| Revenue | ||||
| Consensus | $3.39B | $3.50B | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved